China-based Peijia Medical Ltd (HKG: 9996) has announced that its US-based partner JenaValve Technology Inc. will be acquired by Edwards Lifesciences Corporation through a merger agreement. This strategic acquisition comes as part of Edwards Lifesciences’ efforts to strengthen its structural heart portfolio.
JenaValve had entered into a licensing agreement with Peijia in February 2021, granting the Chinese firm exclusive rights to develop, manufacture, and commercialize the Trilogy transcatheter heart valve system in Greater China for the treatment of aortic regurgitation and stenosis. Peijia rebranded the product as Taurus Trio and has since initiated a multi-center clinical study in China for severe aortic regurgitation, completing patient enrollment in January of this year.
The acquisition by Edwards Lifesciences is not expected to affect the existing licensing agreement, allowing Peijia to continue developing and commercializing Taurus Trio in its specified regions.- Flcube.com
